Patents by Inventor Peter Distefano

Peter Distefano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microbial Ecology Shift Assay
    Publication number: 20190136287
    Abstract: The disclosure provides assay methods for characterizing the effects of an agent on a microbiome of a subject. Moreover, the disclosure provides methods for practical applications of assay results. The biological sample is extracted and the microbial population is enumerated by using signals or markers specific to the microbial species. The enumerated population is subjected to the action of one or many therapeutic agents and the efficiency is assessed by deriving a score based on the effects in the individual samples and in the population of samples.
    Type: Application
    Filed: November 6, 2018
    Publication date: May 9, 2019
    Applicant: Second Genome, Inc.
    Inventors: Rachel Steger, Peter DiStefano, Nadir Mahmood
  • Microbial ecology shift assay
    Patent number: 10150982
    Abstract: The disclosure provides assay methods for characterizing the effects of an agent on a microbiome of a subject. Moreover, the disclosure provides methods for practical applications of assay results. The biological sample is extracted and the microbial population is enumerated by using signals or markers specific to the microbial species. The enumerated population is subjected to the action of one or many therapeutic agents and the efficiency is assessed by deriving a score based on the effects in the individual samples and in the population of samples.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: December 11, 2018
    Assignee: Second Genome, Inc.
    Inventors: Rachel Steger, Peter DiStefano, Nadir Mahmood
  • Microbial Ecology Shift Assay
    Publication number: 20160145670
    Abstract: The disclosure provides assay methods for characterizing the effects of an agent on a microbiome of a subject. Moreover, the disclosure provides methods for practical applications of assay results. The biological sample is extracted and the microbial population is enumerated by using signals or markers specific to the microbial species. The enumerated population is subjected to the action of one or many therapeutic agents and the efficiency is assessed by deriving a score based on the effects in the individual samples and in the population of samples.
    Type: Application
    Filed: March 10, 2014
    Publication date: May 26, 2016
    Applicant: SECOND GENOME, INC.
    Inventors: Rachel Steger, Peter DiStefano, Nadir Mahmood
  • SirT INHIBITORS THAT BIND TO NAD
    Publication number: 20160113903
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: June 4, 2015
    Publication date: April 28, 2016
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew D. Napper, Peter DiStefano, Rory Curtis, Jeffrey Hixon, Thomas E. McDonagh, L. Julie Huber, Jonathan M. Solomon, Russel J. Thomas, Jean-francois Pons
  • Microbiome Modulation Index
    Publication number: 20150337349
    Abstract: The disclosure provides methods and systems for characterizing the effects of an agent on one or more microbial communities.
    Type: Application
    Filed: January 3, 2014
    Publication date: November 26, 2015
    Applicant: Second Genome, Inc.
    Inventors: Justin Kuczynski, Mohan Iyer, Nadir Mahmood, Rachel Steger, Peter DiStefano
  • SirT INHIBITORS THAT BIND TO NAD
    Publication number: 20140163029
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: May 24, 2013
    Publication date: June 12, 2014
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew D. Napper, Peter DiStefano, Rory Curtis, Jeffrey Hixon, Thomas E. McDonagh, L. Julie Huber, Jonathan M. Solomon, Russel J. Thomas, Jean-francois Pons
  • SirT inhibitors that bind to NAD
    Patent number: 8486990
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: July 16, 2013
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • Therapeutic compounds and uses thereof
    Patent number: 7897765
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: March 1, 2011
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
  • SirT Inhibitors That Bind to NAD
    Publication number: 20090306168
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: April 14, 2009
    Publication date: December 10, 2009
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20090264410
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Application
    Filed: February 9, 2009
    Publication date: October 22, 2009
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
  • Therapeutic compounds and uses thereof
    Patent number: 7504506
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: March 17, 2009
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
  • SIRT1 INHIBITION
    Publication number: 20090022694
    Abstract: A method of culturing cells in the presence of a SIRT1 inhibitor is described.
    Type: Application
    Filed: October 17, 2006
    Publication date: January 22, 2009
    Inventor: Peter Distefano
  • Methods of treating a disorder
    Publication number: 20060074124
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: March 11, 2005
    Publication date: April 6, 2006
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh, L. Huber, Jonathan Solomon, Russell Thomas, Jean-Francois Pons
  • Anti-viral therapeutics
    Publication number: 20060019952
    Abstract: Heterocyclic compounds of formula (I), (II), (III), and (IV) and methods of treating or preventing an HIV-mediated disorder by administering a compound of formula (I), (II), (III), or (IV) are described herein.
    Type: Application
    Filed: January 31, 2005
    Publication date: January 26, 2006
    Inventors: Peter Distefano, Alan Watson, Rory Curtis, Bard Geesaman, L. Cannon, Manuel Navia
  • Sulfonamides and uses thereof
    Publication number: 20050261332
    Abstract: Compounds of formulas (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I), (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: April 4, 2005
    Publication date: November 24, 2005
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Jean-Francois Pons, Russell Thomas, Manuel Navia, Thomas Coulter, Jeffrey Saunders, Bard Geesaman
  • Treating a viral disorder
    Publication number: 20050256181
    Abstract: Heterocyclic compounds of formula (I) and methods of treating or preventing an HIV-mediated disorder by administering a compound of formula (I) are described herein.
    Type: Application
    Filed: January 31, 2005
    Publication date: November 17, 2005
    Inventors: Peter Distefano, Alan Watson, Rory Curtis, Bard Geesaman, L. Cannon, Manuel Navia
  • Methods of treating a disorder
    Publication number: 20050250794
    Abstract: Heterocyclic compounds of formula (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I) (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: December 20, 2004
    Publication date: November 10, 2005
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh
  • Methods of treating a disorder
    Publication number: 20050209300
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: September 13, 2004
    Publication date: September 22, 2005
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh, L. Huber, Jonathan Solomon, Russell Thomas, Jean-Francois Pons
  • Therapeutic compounds and uses thereof
    Publication number: 20050187237
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Application
    Filed: November 4, 2004
    Publication date: August 25, 2005
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel Navia, Russell Thomas, Jean-Francois Pons, Jeffrey Saunders
  • Regulation of the growth hormone/IGF-1 axis
    Publication number: 20040121407
    Abstract: This disclosure provides, inter alia, treatments and compositions that alter life span regulation and cellular responses to diseases and disorders by antagonizing the GH/IGF-1 axis. Also provided are methods of screening for agents that can modulate the GH/IGF-1 axis.
    Type: Application
    Filed: September 5, 2003
    Publication date: June 24, 2004
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Peter Distefano, Cynthia A. Bayley, L. Edward Cannon